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TSPO ligand residence time: a new 
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Federico Da Settimo & Claudia Martini
The pharmacological activation of the cholesterol-binding Translocator Protein (TSPO) leads to an 
increase of endogenous steroids and neurosteroids determining benefic pleiotropic effects in several 
pathological conditions, including anxiety disorders. The relatively poor relationship between TSPO 
ligand binding affinities and steroidogenic efficacies prompted us to investigate the time (Residence 
Time, RT) that a number of compounds with phenylindolylglyoxylamide structure (PIGAs) spends 
in contact with the target. Here, given the poor availability of TSPO ligand kinetic parameters, a 
kinetic radioligand binding assay was set up and validated for RT determination using a theoretical 
mathematical model successfully applied to other ligand-target systems. TSPO ligand RT was 
quantified and the obtained results showed a positive correlation between the period for which a drug 
interacts with TSPO and the compound ability to stimulate steroidogenesis. Specifically, the TSPO 
ligand RT significantly fitted both with steroidogenic efficacy (Emax) and with area under the dose-
response curve, a parameter combining drug potency and efficacy. A positive relation between RT and 
anxiolytic activity of three compounds was evidenced. In conclusion, RT could be a relevant parameter 
to predict the steroidogenic efficacy and the in vivo anxiolytic action of new TSPO ligands.
The 18 kDa Translocator Protein (TSPO) is an outer mitochondrial membrane high affinity cholesterol- and 
drug-binding protein abundant in steroid-producing tissues, including gonads, adrenal, and brain1. Previous 
pharmacological, biochemical and genetic studies, as well as in vivo experiments, have provided several lines of 
evidence demonstrating that TSPO is a key member of the multiprotein complex transduceosome, as it participates 
to the cholesterol translocation into mitochondria, which is considered the rate-limiting step of steroidogenesis2.
Consistent with the important role of TSPO in steroidogenesis3–7 and the involvement of steroids in numerous 
fundamental processes8,9, TSPO ligands have been proposed as innovative therapeutic tools in several pathological 
conditions. For example, TSPO ligands have been implicated in axonal regeneration10–12, in anti-inflammatory13, 
anxiolytic14–18, antidepressant19 and anti-post-traumatic stress20 activities, both in animal models, and in indi-
viduals with neurological or psychiatric disorders. To date, phase II and III clinical trials have been concluded or 
are ongoing for the treatment of diabetic peripheral neuropathy (ClinicalTrials.gov identifier: NCT00502515), 
chemotherapy-induced peripheral neuropathy (NCT00868166), and generalized anxiety disorder (NCT00108836).
However, one of the most recurrently issue concerning TSPO ligands consists in the lack of correlation between 
the binding affinity and the in vitro efficacy, including steroidogenic efficacy21. This phenomenon has limited not 
only the identification of lead compounds during the traditional affinity-based drug discovery processes, but also 
questioned the specificity of the observed effects22–24. Recent studies have shown that the affinity of a ligand for its 
target could not directly define its biological action effectiveness, that it may instead be related to the period for 
which a drug interacts with its target defined as ‘Residence Time’ (RT)25,26.
In the present work, it was investigated whether the RT could be a crucial measure to estimate the steroidogenic 
efficacy of a TSPO ligand. To this aim, a number of our previous reported TSPO ligands, belonging to phenylin-
dolylglyoxylamides (PIGAs) was selected based on their different abilities to stimulate in vitro steroidogenesis27–29, 
Table 1. Among such selected TSPO compounds, three presented in vivo anxiolytic effects28,30,31.
As a first step, given the poor availability of kinetic parameters for TSPO ligands, a kinetic radioligand bind-
ing assay was set up and validated for TSPO ligand RT determination by the use of the theoretical mathematical 
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model of Motulsky and Mahan32 (RT = 1/koff, where koff is the dissociation rate constant). This model has been 
applied to several ligand-target systems and shown to be highly accurate in determining the binding kinetics of 
synthetic ligands33–35.
Results
RT determination: initial setting. The [3H]PK11195 radioligand was used as a probe for the determination 
of the kinetic parameters using membrane homogenates of rat kidney, a tissue highly rich in TSPO. Initial exper-
iments were performed to fully characterize [3H]PK11195 binding kinetic parameters as few literature data were 
TSPO ligand
Equilibrium Ki or 
Kd (nM) Kon (M−1. min−1) Koff (min−1)
Kinetically-derived 
Kd = Koff/Kon (nM)
RT = 1/Koff 
(min)
PK11195 (Saturation binding)a 3.60 ± 0.41 NA NA NA NA
PK11195 (Displacement)b 3.39 ± 0.34 NA NA NA NA
PK11195 (Association and 
dissociation)c 8.30 ± 0.64 × 10
6 0.030 ± 0.002 3.61 ± 0.21 33 ± 4
PK11195 (Standard competition 
association)d 9.20 ± 0.71 × 10
6 0.034 ± 0.004 3.70 ± 0.43 29 ± 3
PK11195 (Simplified competition 
assay)e 9.30 ± 0.94 × 10
6 0.029 ± 0.003 3.12 ± 0.37 34 ± 3
Ro5-4864 20.04 ± 2.36 1.29 ± 0.16 × 106 0.031 ± 0.002 24.04 ± 2.01 32 ± 3
PIGA719 12.24 ± 1.1 7.89 ± 0.62 × 106 0.094 ± 0.007 11.95 ± 1.00 11 ± 2
PIGA720 1.40 ± 0.28 2.18 ± 0.29 × 107 0.039 ± 0.004 1.79 ± 0.24 26 ± 2
PIGA745 13.14 ± 1.16 3.84 ± 0.51 × 106 0.058 ± 0.003 15.12 ± 1.16 17 ± 1
PIGA823 3.30 ± 0.31 4.30 ± 0.33 × 106 0.008 ± 0.001 1.86 ± 0.17 127 ± 4
PIGA835 0.91 ± 0.11 5.78 ± 0.56 × 107 0.058 ± 0.005 1.00 ± 0.19 17 ± 1
PIGA839 (M-PIGA) 5.50 ± 0.47 1.69 ± 0.27 × 106 0.009 ± 0.001 5.45 ± 0.60 109 ± 4
PIGA925 12.23 ± 3.14 6.78 ± 0.42 × 106 0.068 ± 0.004 10.01 ± 1.13 15 ± 2
PIGA1128 0.31 ± 0.02 8.10 ± 0.36 × 107 0.018 ± 0.001 0.22 ± 0.05 55 ± 2
PIGA1138 0.34 ± 0.03 4.30 ± 0.30 × 107 0.007 ± 0.001 0.17 ± 0.03 141 ± 4
PIGA1214 343.01 ± 15.94 9.05 ± 0.51 × 104 0.030 ± 0.004 332.05 ± 15.04 39 ± 2
Table 2. TSPO ligand binding affinity and kinetic parameters obtained by equilibrium binding and kinetic 
association assays. Values are means ± SEM of three experiments performed in duplicate. NA = not applicable. 
a[3H]PK11195 binding performed using increasing concentration of radioligand. bdisplacement of [3H]PK11195 
binding using increasing concentration of PK11195. cthe binding kinetics of [3H]PK11195 were determined by 
‘traditional’ association and dissociation assays. dthe binding kinetics of unlabeled PK11195 were determined 
by adding a concentration equivalent to one-, three- and ten-fold the Ki value of PK11195. ethe binding kinetics 
of unlabeled PK11195 were determined by adding a concentration equivalent to only three-fold the Ki value of 
PK11195.
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Compd. R5 Ar R1 R2
PIGA719a H C6H5 (CH2)2CH3 (CH2)2CH3
PIGA720a H C6H5 (CH2)5CH3 (CH2)5CH3
PIGA745a Cl C6H5 (CH2)5CH3 (CH2)5CH3
PIGA835a Cl C6H4-4-Cl (CH2)3CH3 (CH2)3CH3
PIGA925b NO2 C6H5 (CH2)5CH3 (CH2)5CH3
PIGA1214c H C6H4-4-COOH (CH2)5CH3 (CH2)5CH3
PIGA839a H C6H4-4-CH3 (CH2)2CH3 (CH2)2CH3
PIGA823b Cl C6H4-4-Cl CH2CH3 CH2C6H5
PIGA1128c H naphth-2-yl- (CH2)2CH3 (CH2)2CH3
PIGA1138c H naphth-2-yl- CH3 (CH2)4CH3
Table 1.  Structures of PIGAs, PK11195, and Ro5-4864. aPrimofiore et al., 2004. bDaSettimo et al., 2008. 
cBarresi et al., 2015.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:18164 | DOI: 10.1038/srep18164
available36,37. [3H]PK11195 equilibrium binding parameters, Kd and Bmax, were 3.60 ± 0.41 nM and 6498 ± 500 
fmol/mg of proteins, respectively (Table 2). The Ki value of unlabeled PK11195 determined by [3H]PK11195 
displacement binding assay was 3.39 ± 0.34 nM (Table 2).
The koff determination was obtained by: (i) pre-labelling of TSPO to equilibrium with one [3H]PK11195 concen-
tration (approximately 10 × Kd) that provides high initial TSPO occupancy; (ii) inducing radioligand dissociation 
by addition of TSPO-saturating concentration (about 1000 × Kd) of unlabeled competing compound PK11195. 
Then, the dissociation time-course was analyzed using an exponential function. An example of [3H]PK11195 
dissociation kinetic curve is shown in Fig. 1A; [3H]PK11195 dissociation was monophasic and gave a half-life 
of radioligand-TSPO complex (t1/2) of 23 min, which when applied to Equation 1 (see Materials and Methods 
section) gave a koff of 0.030 ± 0.002 min−1. The RT value, which is the reciprocal of koff, was 33 ± 4 min (Table 2).
To determine [3H]PK11195 kon, a family of association kinetic curves using a range of radioligand concentra-
tions were constructed. Each association curve was monitored until equilibrium. In Fig. 1B, a representative [3H]
PK11195 association kinetics curve is showed. If [3H]PK11195 binding follows a simple law of mass action model, 
the observed kinetic association constant (kob) should increase in a linear manner with radioligand concentration38. 
Figure 1. [3H]PK11195 kon and koff by ‘traditional’ dissociation and association kinetics assays. (A) 
[3H]PK11195 binding dissociation Kinetics: Data were best fitted using a one-phase exponential decay function 
to produce a t1/2 estimate. This was converted into a koff value by using Equation 1, as detailed in the Materials 
and Methods section. The ordinate reports the specific [3H]PK11195 binding expressed as fmol/mg of protein. 
The abscissa reports the incubation time expressed in min. (B,C) [3H]PK11195 binding association Kinetics: a 
family of association kinetics curves were constructed incubating membrane homogenates with a range of [3H]
PK11195 concentrations as described in the Materials and Methods section. Data were fitted using a one phase 
exponential association function to yield a kob. (B) A representative association curve performed using 23 nM 
[3H]PK11195 up to 5 h incubation time is showed. The ordinate reports the specific [3H]PK11195 binding 
expressed as fmol/mg of protein. The abscissa reports the incubation time expressed in min. (C) kobs values 
plotted against the corresponding [3H]PK11195 concentration employed are showed.
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In this case, the slope of the line should equate to the association rate and extrapolation of the plot to the Y-intercept 
(at x = 0) should equal the dissociation rate39. When the kob values were plotted against radioligand concentration, 
the data were consistent with a straight line (r2 = 0.98), indicating that binding of [3H]PK11195 to TSPO was 
consistent with the law of mass action (Fig. 1C). The obtained values were kon = 8.30 ± 0.64 × 106 M−1 min−1 and 
koff = 0.030 ± 0.002 min−1 (Fig. 1C and Table 2). The kinetically derived Kd (3.61 ± 0.21 nM; kinetic Kd = koff/kon) 
was in good agreement with the value obtained from [3H]PK11195 saturation experiments (equilibrium 
Kd = 3.60 ± 0.41) (Table 2).
RT Determination: TSPO ligand koff and kon by competition kinetic association assays. With the 
predetermined kon (k1) and koff (k2) values of [3H]PK11195 from ‘traditional’ kinetic association and dissociation 
experiments, kon (k3) and koff (k4) of an unlabeled ligand could be determined by fitting the kinetic parameters into 
the model of ‘Kinetics of competitive binding’ described in Materials and Methods section. This method is based 
on a framework developed by Motulsky and Mahan32, where an unlabeled competitor is added simultaneously with 
a radioligand to the receptor preparation of interest. Then, the experimentally derived rate of specific radioligand 
binding can be modelled to provide the association and dissociation rates of the unlabeled compound.
As a first step, the competition association assay was performed using unlabeled PK11195. Three different 
concentrations of PK11195 were tested to ensure that the rate parameters calculated were independent of ligand 
concentration (Fig. 2A). The kon (k3) and koff (k4) values determined in this assay were 9.20 ± 0.71 × 106 M−1 min−1 
and 0.034 ± 0.004 min−1, respectively (Table 2; PK11195 RT = 29 ± 3 min), which corresponded rather well to 
the kinetics rates determined by ‘traditional’ association and dissociation experiments (Table 2). Moreover, the 
kinetically derived Kd obtained from the competition association assay for unlabeled PK11195 was similar to Ki 
obtained from displacement experiments and Kd derived from saturation experiments (Table 2). Taken together, 
these findings proved that the competition association assay could be applied to determine the binding kinetics 
of an unlabeled TSPO ligand.
The competition association assay approach has been shown to be highly accurate in determining the bind-
ing kinetics at several targets33–35. However, when the kinetics of multiple compounds need to be determined, 
the standard model is laborious and time consuming because it implies the use of three concentrations of each 
unlabeled ligand. Recently, it has been demonstrated that the use of one concentration of unlabeled ligand is able 
to yield an accurate determination of kinetic rates of unlabeled ligands at their receptor, too34. These findings 
prompted us to modify the three-concentration-dependent assay into a one-concentration-based method. The data 
analyzed at three-fold Ki of unlabeled PK11195 showed a comparable result (kon = 9.30 ± 0.94 × 106 M−1 min−1 
and Koff =   0.029 ±   0.003 min−1; RT =   34 ±   3 min) (Fig.  2B) to that generated in a standard 
(three-concentration-dependent) competition association experiment (Table 2). This result indicates that this 
simplified method is strong enough to quantify the binding kinetics, which eventually enables testing in a faster 
medium-throughput format, yet without loss of accuracy.
By using the ‘simplified’ competition kinetic association assay, the TSPO ligands, including the classical ones 
Ro5-4864 and PIGA compounds (Table 1) were tested at three-fold respective Ki concentration and data were 
Figure 2. PK11195 kon and koff by competitive association kinetics assays. (A) The curves were obtained by 
incubation of membranes with either radioligand alone or radioligand and unlabeled PK11195 for the indicated 
time points. Data were fitted to the equation 2 to calculate the kon and koff of PK11195. Representative curves 
obtained using one-, three-, ten-fold Ki value of unlabeled PK11195. (B) Representative curves obtained using 
three-fold Ki value of unlabeled PK111195.
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fitted using Equation 2 (see Material and Methods section) to calculate kon and koff simultaneously (Table 2). 
Competition association assay results demonstrated two patterns of [3H]PK11195 binding in dependence of the 
competing ligand used. In general, if the competitor dissociates from its target faster than the radioligand, the 
specific binding of the radioligand will approach its equilibrium time slowly and monotonically. However, when 
the competitor dissociates slower, the association curve of the radioligand will consist of two phases, starting with a 
typical “overshoot” and then a decline until a new equilibrium is reached. The results obtained are consistent with a 
rapid (PIGA719, PIGA720, PIGA745, PIGA835, PIGA925, PIGA1214, Ro5-4864) and a slow (PIGA823, PIGA839 
(M-PIGA), PIGA1128, PIGA1138) dissociation rate of the ligands from TSPO. Representative curves for rapid 
dissociating (PIGA1214) and slow dissociating (PIGA1138) TSPO ligands were shown in Fig. 3A,B, respectively.
To validate the rate constants, the kinetically derived Kd were compared with Ki obtained from equilibrium 
competition binding experiments. Notably, an excellent correlation (r2 = 0.999, p < 0.0001; Fig. 3C) was observed 
between Ki determined in equilibrium-binding studies and Kd values derived from the competition association 
assays (Table 2). This further proved that the simplified model is able to quantify the association and dissociation 
rates of unlabeled TSPO ligands accurately.
TSPO ligand steroidogenic efficacy. The steroidogenic efficacy of TSPO ligands was measured in terms of 
pregnenolone production in C6 glioma cells following exposure with increasing ligand concentrations for a fixed 
incubation time. For each TSPO ligand, potency (EC50 value) was derived by sigmoidal concentration-dependent 
curve and efficacy (Emax value, relative to the highest tested concentration of TSPO ligand) was calculated with 
respect to control (DMSO-treated sample), corresponding to basal pregnenolone production. In Fig. 4, the curves 
of TSPO ligand-stimulated pregnenolone production are shown. The EC50 and Emax values are detailed in Table 3. 
Specifically, among all tested TSPO ligands, M-PIGA, PIGA823 and PIGA1138 had the highest efficacy. The 
majority of the tested TSPO ligands showed efficacy to stimulate pregnenolone production ranging from 140% 
up to 179% (basal value was set to 100%).
Figure 3. Competitive association kinetics assays of TSPO ligands and correlation between Ki and ‘Kinetic 
Kd’ values. (A) Representative curves obtained using three-fold Ki of PIGA1214 (B) or PIGA1138. (C) Ki values 
were obtained from [3H]PK11195 competition binding experiments at equilibrium. The kinetically Kd values 
were derived from the competition association experiments.
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Correlation between RT and steroidogenesis efficacy. In Fig. 5, correlation analyses are reported 
between the TSPO ligand-mediated steroidogenic potency or efficacy and either binding affinity (Ki) or Residence 
Time (RT). The steroidogenic potency of TSPO ligands correlated with the logarithm of Ki (Pearson r = 0.6553; 
P = 0.0207; r2 = 0.4295) (Fig. 5A), in agreement with previous reported data40–42, but not with RT (Pearson 
r = 0.08962; P = 0.7818; r2 = 0.0803) (Fig. 5B). The steroidogenic efficacy of TSPO ligands did not significantly 
correlate with Ki (Pearson r = − 0.3489; P = 0.2663; r2 = 0.1217) (Fig. 5C). Conversely, a highly significant corre-
lation was observed between steroidogenic efficacy and RT (Pearson r = 0.8526; P = 0.0004; r2 = 0.7270) (Fig. 5D). 
Correlation analyses were also performed between the logarithm of Ki or RT and the area under the dose-response 
curve (AUC), a value that combines potency and efficacy of a drug into a single parameter43. When the relationship 
Figure 4. Effects of the TSPO ligands (PK11195, Ro4-54864, PIGAs) on glioma C6 cell steroid synthesis. 
(A) Dose-dependent effects of the compounds with longest RTs (> 40 min) on C6 steroidogenesis (B) Dose-
dependent effects of the compounds with shortest RTs (< 40 min) on C6 steroidogenesis. C6 cells were cultured 
with increasing concentrations of ligands (0–100 μ M) for 2 h in serum-free media and pregnenolone released 
into the media was assessed by ELISA. The results are expressed as the mean of three separate experiments, and 
data were fitted with a dose–response curve with Hill slope of 1.0.
TSPO ligand EC50 (μM)
Emax (at 100 μ M) 
(vehicle set to 
100%)
Equilibrium Ki or Kd 
(nM) RT (min)
PK11195 19.5 ± 1.8 153 ± 4 3.30 ± 0.34 34 ± 3
Ro5-4864 36.2 ± 2.5 150 ± 4 20.04 ± 2.36 32 ± 3
PIGA719 12.9 ± 1.5 146 ± 2 12.24 ± 1.1 11 ± 2
PIGA720 29.7 ± 3.1 144 ± 4 1.40 ± 0.28 26 ± 2
PIGA745 34.6 ± 3.6 140 ± 5 13.14 ± 1.16 17 ± 1
PIGA823 12.2 ± 1.3 272 ± 11 3.30 ± 0.31 127 ± 4
PIGA835 25.6 ± 2.3 149 ± 4 0.91 ± 0.11 17 ± 1
PIGA839 (M-PIGA) 16.3 ± 1.4 254 ± 5 5.50 ± 0.47 109 ± 4
PIGA925 9.71 ± 1.0 166 ± 5 12.23 ± 3.14 15 ± 2
PIGA1128 26.1 ± 1.5 179 ± 7 0.31 ± 0.02 55 ± 2
PIGA1138 13.1 ± 1.4 275 ± 5 0.34 ± 0.03 141 ± 4
PIGA1214 92.0 ± 5.6 141 ± 4 343.01 ± 15.94 39 ± 2
Table 3. Experimental kinetic/thermodynamic data and steroidogenic parameters for TSPO ligands. 
Values are means ± SEM of three experiments performed in duplicate. Potency (EC50 value) of TSPO 
ligands was derived by sigmoidal concentration-dependent curves. Efficacy (Emax) corresponds to amount of 
pregnenolone production by 100 μ M TSPO ligand concentration.
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between AUC and the logarithm of Ki was analyzed, no correlation was found (Pearson r = − 0.3308; P = 0.2937; 
r2 = 0.1094) (Fig. 5E). On the contrary, the AUC values significantly correlates with logarithm of RT (Pearson 
r = 0.7563; P = 0.0044; r2 = 0.5720) (Fig. 5F).
Discussion
The TSPO drug discovery has followed the traditional thermodynamic equilibrium constant (Kd or Ki) paradigm 
to identify lead compounds. However, binding kinetics parameters, especially the Residence Time of a drug on 
its target, are becoming critical predictors for in vivo drug efficacy25,26. In the present manuscript, accurate kinetic 
parameters for TSPO ligands were obtained by the use of the mathematical model of Motulsky and Mahan32 that 
has been shown to be highly accurate in determining the binding kinetics of unlabeled ligands at several targets33–35. 
This mathematical model has overcame the high cost of compound radiolabeling in order to measure directly the 
association and dissociation rates of a drug to the target44. For binding kinetics determination, classical TSPO 
Figure 5. Correlation analyses between kinetic/thermodynamic and steroidogenic parameters. TSPO 
compound names were included next to their respective data points (for PIGA compounds only the ID 
numbers were shown). (A) Scatter plot of the EC50 values against thermodynamic parameters (logKi) of test 
TSPO ligands; (B) Scatter plot of the EC50 values against kinetic parameters (logRT) of test TSPO ligands;  
(C) Scatter plot of the Emax values against thermodynamic parameters (logKi) of test TSPO ligands; (D) Scatter 
plot of the Emax values against kinetic parameters (logRT) of test TSPO ligands; (E) Scatter plot of the AUC 
values against thermodynamic parameters (logKi) of test TSPO ligands; (F) Scatter plot of the AUC values 
against kinetic parameters (logRT) of test TSPO ligands.
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ligands (the isoquinoline PK11195 and the benzodiazepine Ro5-4864) and the TSPO ligand PIGAs27–29 (Table 1) 
were selected. Specifically, the majority of the tested TSPO compounds resulted rapid dissociating competitors 
of [3H]PK11195 binding sites (PIGA719, PIGA720, PIGA745, PIGA835, PIGA925, PIGA1124 and Ro5-4864) 
(Table 2). Conversely, the compound PIGA823, PIGA839 (M-PIGA), PIGA1128, and PIGA1138 resulted slow 
dissociating competitors (Table 2). Concerning the molecular determinants underling the TSPO-ligand kinetic 
interactions, no literature data are available. The estimation of the RT for a large number of TSPO ligands could 
support in determining new Structure Activity Relationship (SAR) based on the ligand kinetic parameters. Indeed 
up to date, SAR has been rationalized only on binding affinity parameters using pharmacophore hypotheses27,28,45,46 
and a 3D model29 based on the newly published NMR structure of mouse TSPO (PDB code 2MGY)47. Notably, 
the steroidogenic efficacy of TSPO ligands did not correlated with the compound binding affinity21, suggesting 
the limitation of a SAR affinity-based strategy.
Herein, a highly significant positive correlation between the efficacy to stimulate in vitro steroidogenesis of 
TSPO ligands and their kinetic parameter RT was found. Remarkably, the efficacy did not correlate with the 
thermodynamic equilibrium constant Ki of the TSPO ligands. Taken together, these results indicate that the key 
factor for robust steroidogenic TSPO ligand efficacy is not the binding affinity per se, but rather the time the 
compound spends on the target. Such this novel concept for TSPO ligands suggests the importance of using the 
RT parameter rather than the constant Ki during the in vitro characterization of TSPO compounds in relation to 
their steroidogenic activity.
The results discussed thus far allow us to outline a preliminary efficacy-based SAR for the interaction of PIGAs 
with TSPO. Data in Table 2 suggest a cooperative effect between the size of the substituents on the amide nitrogen 
and the lipophilicity of the aryl group at the 2-indole position. In particular, high retention times and high effi-
cacy seem to derive from the presence of an highly lipophilic moiety at the 2-position (C6H4-4-CH3, C6H4-4-Cl, 
naphth-2-yl), combined with at least one of the two N-alkyl groups with a number of carbon atoms in the 1–3 
range (PIGA839, PIGA823, PIGA1138).
From a therapeutic perspective, this new concept paves the way to identify TSPO drugs with promising phar-
macological activities, including anxiolytic effects. Scientific community has directed particular interest to TSPO 
ligands for the treatment of anxiety-related disorders, as they have shown fast-acting anxiolytic properties with-
out the typical side-effects of benzodiazepine-based regimes15,48,49. Differently to benzodiazepines, which act as 
direct modulators of the GABAA receptor, TSPO ligands generally enhance GABAergic neurotransmission via the 
promotion of neurosteroidogenesis without direct effects at the GABAA receptor17. Neurosteroids, especially the 
3-alpha-reduced steroids, are potent positive allosteric modulators of GABAA receptor17. Consistent with such evi-
dences, previous our data30 have shown that the medium from PIGA839 (M-PIGA)-treated human glial cell model 
contained high levels of allopregnanolone, one of the major positive GABAA receptor allosteric modulator. The 
conditioned medium potentiated the 36Cl− uptake into cerebral cortical synaptoneurosomes, suggesting a positive 
modulation of GABAA receptor activity30. The PIGA ligands have been already tested for their potential in vivo 
anxiolytic effects by means of the Elevated Plus-Maze (EPM) paradigm in the rat (PIGA823: compound number 
32 in28, and PIGA839 (M-PIGA) in30). In the EPM test, either PIGA823 and PIGA839 (M-PIGA), characterized 
by long RT and high steroidogenic efficacy, have elicited a significant anxiolytic activity (PIGA823: RT = 127 min, 
Emax pregnenolone = 272%; PIGA839 (M-PIGA): RT = 109 min; Emax pregnenolone = 254%). Conversely, it has 
been documented that the classical TSPO ligand PK11195 and Ro5-4864, which are characterized by shorter RT 
and lower pregnenolone Emax (PK11195: RT = 34 min, Emax pregnenolone = 153%; Ro5-4864: RT = 32 min; Emax 
pregnenolone = 150%) than PIGA823 and PIGA839 (M-PIGA), does not determine anxiolytic effect in EPM test50. 
In addition, PK11195 has been used to antagonize anxiolytic effects exerted by other TSPO ligands (high steroido-
genic efficacy, such as FGIN-1-27, FGIN-1-44 and YL-IPA08)4,6,19. These retrospective assessments suggested that a 
long RT predicts the anxiolytic activity of a TSPO ligand. Moreover, RT is a better efficacy predictive measure than 
the thermodynamic equilibrium constant Kd or Ki. Indeed, PK11195, PIGA823 and PIGA839 (M-PIGA) showed 
comparable Ki values (PK11195: Ki = 3.60 nM; PIGA823 Ki = 3.30 nM; PIGA839 (M-PIGA) Ki = 5.50 nM), irre-
spective to their in vivo activity. Consistent with our data, it has been recently demonstrated discrepancy between 
the Ki of known anxiolytic TSPO ligands (Etifoxine and XBD173) and the enhancement of neurosteroid synthesis21. 
Specifically, Etifoxine, which is already clinically approved for the treatment of anxiety-related disorders, is more 
potent to stimulate neurosteroidogenesis than XBD173, although its binding affinity to TSPO was approximately 
140 fold lower than XBD173. These findings have suggested that the efficacy of such TSPO ligands to stimulate neu-
rosteroid synthesis, thereby leading to anxiolytic effects, cannot be concluded from their binding affinity to TSPO.
In conclusion, the present results indicate that the Residence Time is a better parameter to estimate the steroi-
dogenic effectiveness of a TSPO ligand compared to the equilibrium thermodynamic parameters, corroborating the 
importance of the drug-target interaction dynamics in predicting the drug efficacy. These findings, in combination 
with the future availability of a RT database, open the way to optimize TSPO ligands as promising therapeutic tools.
Materials and Methods
Reagents. [3H]PK11195 (Specific Activity, 85.7 μ Ci/nmol) and Ultima Gold scintillation mixture were obtained 
from Perkin-Elmer Life Sciences. PK11195, protease inhibitors and GF/C glass fiber filters were purchased from 
Sigma-Aldrich. 2-arylindol-3-ylglyoxyl derivatives were synthesized as previously described27–29. Dulbecco’s modi-
fied Eagle’s medium, fetal bovine serum, L-glutamine, penicillin, and streptomycin were from Lonza (Milano, Italy). 
Enzyme immunoassay (ELISA) for pregnenolone measurement was obtained from IBL (Hamburg, Germany). 
SU10603 and trilostane were gifts from Novartis Farma (Varese, Italy) and Dr. Zister (University of Dublin, Dublin, 
Ireland), respectively. Protein assay reagent was obtained by Bio-Rad Laboratories Inc. All other chemical reagents 
were obtained by commercial sources.
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[3H]PK11195 binding saturation assays. Membranes from rat kidneys were prepared as described pre-
viously51. All the experimental procedures were carried out following the guidelines of the European Community 
Council Directive 86–609 and have been approved by the Committee for animal experimentation of the University 
of Pisa. The resulting membrane pellets were aliquoted and frozen at –20 °C. For all radioligand binding assays, 
an aliquot of membranes was thawed, suspended in assay buffer (AB, Tris-HCl 50 mM, pH 7.4) and homogenized 
using Ultraturrax. In cell membrane homogenate, protein content was measured by the Bradford method52 using 
the Bio-Rad Protein Assay reagent.
Membrane homogenates (30 μ g of proteins) were incubated with increasing [3H]PK11195 concentrations 
(0.1–20 nM; Specific Activity, 85.7 μ Ci/nmol) in the final volume of 500 μ l of AB for 90 min at 0 °C. Non-specific 
[3H]PK11195 binding was obtained in the presence of 1 μ M PK11195 (solubilized with ethanol); the solvent 
concentration was less than 1% and did not interfere with specific [3H]PK11195 binding. After incubation time, 
samples were filtered rapidly under vacuum through GF/C glass fiber filters. After being washed three times with 
3 ml of AB, radioactivity trapped on the filter was measured by liquid scintillation counter (TopCount; PerkinElmer 
Life and Analytical Sciences; 65% counting efficiency).
PIGA TSPO ligands. The compounds PIGA719, PIGA720, PIGA745, PIGA835, PIGA839 (M-PIGA)27, 
PIGA925, PIGA823, PIGA92228, PIGA1214, PIGA1128, PIGA1138 were synthesized following experimental 
procedure previously described by us29.
[3H]PK11195 binding displacement assays. Membrane homogenates (20 μ g of proteins) were incubated 
with increasing concentrations of unlabeled TSPO ligand and 1 nM [3H]PK11195 (Specific Activity, 85.7 μ Ci/nmol) 
in the same above described conditions. The inhibitory constant (Ki) determination was performed for PK11195 
and additional compounds, including Ro5-4864 (Sigma-Aldrich Milano, Italy) and PIGA ligands27–29.
[3H]PK11195 binding ‘traditional’ kinetics assays. The [3H]PK11195 koff was determined by incubat-
ing membrane homogenates (30 μ g of protein) with [3H]PK11195 at one fixed concentration, corresponding to 
approximately ten-fold its Kd value, in a final volume of 500 μ l AB at 0 °C. To obtain [3H]PK11195 concentration, 
corresponding to 10 × Kd, approximately 1.5 μ Ci of [3H] had to be added per assay. Since 1 μ Ci of [3H] per assay rep-
resents the practical upper limit of radiotracer usage, the radioligand was diluted with unlabeled PK11195 to reduce 
its specific activity. In brief, the specific activity of [3H]PK11195 was reduced to ¼ of its initial original specific 
activity (Specific Activity, 21.4 μ Ci/nmol). This allowed us to use a maximum amount of approximately 0.38 μ Ci 
of [3H] per sample. After a pre-incubation of 2 h, the dissociation was initiated by addition of 5 μ M PK11195. The 
amount of radioligand bound to TSPO was measured at various time intervals for a total duration of 2 h.
To determine [3H]PK11195 kon, the observed association rate constant (kob) was calculated at different con-
centrations of [3H]PK11195 (Specific Activity, 21.4 μ Ci/nmol). The experiment was initiated (t = 0) by addition 
of [3H]PK11195 to membrane homogenates (30 μ g of proteins) in a final volume of 500 μ l of AB and incubated 
up to 2 h. To establish whether [3H]PK11195 binding was stable for longer times than 2 h, incubation times were 
prolonged up to 5 h in some kinetic association binding assays. Free [3H]PK11195 was separated at multiple time 
points to construct association kinetic curves. Incubations for both the [3H]PK11195 dissociation and association 
assays were terminated and samples were obtained as above described.
Unlabeled TSPO ligand competition kinetic association assays. The unlabeled TSPO ligand kinetic 
parameters were assessed using the theoretical model of Motulsky and Mahan32. Unlike methods in which one com-
pound is pre-equilibrated with the receptor, this approach involves the simultaneous addition of both radioligand 
and competitor to receptor preparation, so that at t = 0 all receptors are unoccupied. [3H]PK11195 (approximately 
30 nM; SA, 21.4 μ Ci/nmol) was added simultaneously with unlabeled compound to membrane homogenates 
(30 μ g of proteins) in a final volume of 500 μ l AB. The degree of bound to TSPO was assessed at multiple time 
points by filtration harvesting and liquid scintillation counting, as above described. The assay was performed using 
concentration of PK11195 corresponding to one-, three- and ten-fold its Ki. For ‘simplified’ competition kinetic 
association assays, the experiments were performed using concentration of unlabeled TSPO ligands corresponding 
to three-fold their Ki.
Pregnenolone measurement. Pregnenolone assessment was performed using rat C6 glioma cells as an 
in vitro steroidogenic model, as previously described29. C6 cells were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum, 2 M L-glutamine, penicillin at 100 U/mL, and streptomycin 
at 100 μ g/mL. Cell cultures were maintained in a humidified atmosphere of 5% CO2 and 95% air at 37 °C. Before 
the measurement of pregnenolone production, the cells (seeded in 96-well plates at a density of ∼ 105 cells/well) 
were washed 2 times with a salt medium, consisting of 140 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM MgSO4, 
10 mM glucose, and 10 mM N-2-hydroxyethylpiperazine-N′ -2-ethanesulfonic acid(HEPES)–NaOH (pH 7.4) 
plus 0.1% bovine serum albumin. For the measurement of pregnenolone secreted into the medium, the further 
metabolism of pregnenolone was blocked by the addition of trilostane (25 μ M) and SU10603 (10 μ M) (inhibitors 
of 3β -hydroxysteroid dehydrogenase and 17α -hydroxylase, respectively) to the salt medium. The addition of 
PK11195, Ro5-4864 or PIGAs to the C6 cells was accomplished by complete change of the salt medium to a medium 
containing increasing concentrations of the compounds (ranging from 0 to 100 μ M). The final concentration of 
vehicle (DMSO or ethanol) was constant for all of the samples and did not exceed 0.5% (v/v), a concentration that 
did not affect steroid production on its own. At the end of the incubation periods (2 hours), the cell medium was 
collected and the amount of pregnenolone secreted into the medium was quantified by an enzyme immunoassay, 
under the conditions recommended by the supplier. Cross-reactivity with other steroids was typically less than 1% 
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and cross-reactivity with progesterone is 6%. The sensitivity of the assay was 0.05 ng/ml. Unknown samples were 
compared with concurrently run standards of pregnenolone using a one-site competition model (calibrator curve).
Data analysis. All experiments were analyzed by either linear or non linear regression using Prism 5.0 
(GraphPad Software Inc., San Diego, CA). Equilibrium Kd and maximum binding sites (Bmax) values of [3H]
PK11195 at TSPO were obtained by computational analysis of saturation curves. Competition displacement binding 
were fitted to sigmoidal (variable slope) curves. The concentration of test compounds that inhibited [3H]PK11195 
binding to kidney membranes by 50% (IC50 values) obtained from the inhibition curves were converted to Ki values 
using the method of Cheng and Prusoff53. [3H]PK11195 dissociation data were fitted to a one-phase exponential 
decay function and the t1/2 value obtained was transformed into a koff rate using the Equation:
=
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[3H]PK11195 association data were fitted to a single phase exponential association function to calculate an observed 
rate constant kob.
Association and dissociation rates for unlabeled TSPO ligands were calculated by fitting the data in the com-
petition association model using the ‘kinetics of competitive binding’ assay, defining the amount of radioligand 
bound to receptor ([RL]) as a function of time32:
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The abbreviations used are: [RL] is the receptor-radioligand complex, as the specific [3H]PK11195 binding (fmol/
mg of protein); [L] is the concentration of [3H]PK11195 used (nM), [I] is the concentration of unlabeled ligand 
(nM); t is the time in min; N is the total concentration of TSPO (fmol/mg of protein); k1 and k2 are the kon (M−1 
min−1) and koff (min−1) of [3H]PK11195, respectively, determined from the radioligand association assay; k3 is the 
kon value (M−1 min−1) of the unlabeled ligand; k4 is the koff value (min−1) of the unlabeled ligand.
Correlation analyses were performed by Pearson correlation.
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